Study of Cord Blood-derived CAR NK Cells Targeting CD19/CD70 in Refractory/Relapsed B-cell Non-Hodgkin Lymphoma
Study Details
Study Description
Brief Summary
To find the highest tolerable dose of dualCAR-NK19/70 (a type of cell therapy) that can be given to patients who have B-cell lymphoma that is relapsed or refractory.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 1/Phase 2 |
Detailed Description
Primary Objectives:
--The primary objective is to determine the safety and identify the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) of dualCAR-NK19/70 in patients with r/r B-cell lymphomas.
Hypothesis: DualCAR-NK19/70 will be safe, well-tolerated, and effective in patients with r/r B-cell lymphomas.
Secondary Objectives:
--The secondary objective is to determine the efficacy in adults with r/r LBCL and FL grade 3B treated at the MTD or RP2D of dualCAR-NK19/70. Although the clinical benefit of dualCAR-NK19/70 has not yet been established, the intent of offering this treatment is to provide a possible therapeutic benefit, and thus the patient will be carefully monitored for tumor response and symptom relief in addition to safety and tolerability. Secondary endpoints include overall response rate (ORR; including CR + PR) and CR rate as defined by the Lugano Classification response criteria for malignant lymphoma, DOR, PFS, and OS.
Exploratory Objectives:
--The exploratory objectives are to assess the cellular kinetics and pharmacodynamic effects of dualCAR-NK19/70 and to evaluate biomarkers associated with response, resistance, and toxicity after administration of dualCAR-NK19/70 in blood and tumor samples.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Part 1 (dose escalation) and Part 2 (dose expansion) Part 1 (dose escalation) the dose of dualCAR-NK19/70 participants receive will depend on when you join this study. Up to 3 dose levels of dualCAR-NK19/70 will be tested. About 3-6 participants will be enrolled at each dose level. The first group of participants will receive the lowest dose level of dualCAR-NK19/70. Each new group will receive a higher dose of dualCAR-NK19/70 than the group before it, if no intolerable side effects were seen. This will continue until the highest tolerable dose of dualCAR-NK19/70 is found. Part 2 (dose expansion) Participants will receive dualCAR-NK19/70 at the recommended dose that was found in Part 1. |
Drug: dualCAR-NK19/70 cell
Given by IV (vein)
Other Names:
|
Outcome Measures
Primary Outcome Measures
- incidence of dose limiting toxicity(DLTs) [up to 28 days]
To evaluate the safety,tolerabitility,and determine the recommended dosage of cord blood-derived CAR NK cells targeting CD19/CD70
Secondary Outcome Measures
- Objective Response Rate（ORR） [6 months]
To determine the anti-tumor effectivity of CB dualCAR-NK19/70
- Complete Remission Rate(CRR) [3 months]
To determine the anti-tumor effectivity of CB dualCAR-NK19/70
- Overall survival(OS) [Up to 3 years]
To determine the anti-tumor effectivity of CB dualCAR-NK19/70
- Duration of Response(DOR) [Up to 3 years]
To determine the anti-tumor effectivity of CB dualCAR-NK19/70
- progression-free survival(PFS) [Up to 3 years]
To determine the anti-tumor effectivity of CB dualCAR-NK19/70
Other Outcome Measures
- Incidence of Adverse Events [through study completion; an average of 1 year,up to 3 years]
Type, frequency, and severity of adverse events,Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5
- Exploratory Objectives [Up to 3 years]
The exploratory objectives are to assess the cellular kinetics and pharmacodynamic effects of dualCAR-NK19/70 and to evaluate biomarkers associated with response, resistance, and toxicity after administration of dualCAR-NK19/70 in blood and tumor samples.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Voluntarily participate in the study and sign the informed consent;
-
Age 18-75, male and female;
-
Histologically confirmed diffuse large B-cell lymphoma (DLBCL), transformed follicular lymphoma (tFL), primary mediastinal B-cell lymphoma (PMBCL), mantle cell lymphoma (MCL), and other Indolent B-cell NHL transforming types:
（A） Relapsed or Refractory DLBCL and tFL after 2 lines Immunotherapy or chemotherapy ; （B） Definition of Refractory large B cell lymphoma (SCHOLAR - 1 Research Standard) : disease progression after more than 4 courses of standard Immunotherapy or chemotherapy; Or the time of disease stabilization ≤ 6 months; Or disease progression or recurrence within 12 months after autologous hematopoietic stem cell transplantation (auto-HSCT); （C） Relapsed or Refractory MCL must be 1 line with immune chemotherapy; BTK inhibitors are resistant or intolerant as 2-line therapy; （D） Relapsed or Refractory disease after chemotherapy including rituximab and anthracycline.
-
There was at least one measurable lesion with the longest diameter ≥ 1.5cm;
-
Estimated life expectancy of more than 12 weeks other than primary disease;
-
Previously confirmed diagnosis as CD19+ or CD70+ B-NHL.
-
Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 3.
-
Adequate reserve of organ function:
（A） Serum alanine aminotransferase (ALT) / aspartate aminotransferase (AST) ≤2.5 times the Upper Limit of Normal (ULN) for age; （B） A creatinine clearance (as estimated either by a direct urine collection or Cockcroft-Gault Equation) > 60mL/min; （C） Total bilirubin and alkaline phosphatase ≤1.5 times the Upper Limit of Normal (ULN) for age; （D） glomerular filtration rate > 50 ml/min （E） Cardiac ejection fraction (EF) ≥ 45% as determined by an echocardiogram (ECHO) or Multigated Radionuclide Angiography (MUGA); （F） Baseline oxygen saturation >92% on room air （G） Absolute neutrophil count > 1000/μL, Platelet count > 45,000/μL ,Hemoglobin > 80g/L;
-
Once previous autologous hematopoietic stem cell transplantation (auto-HSCT) is allowed;
-
For systemic therapy(Such as systemic chemotherapy, systemic radiotherapy and immunotherapy), at least 3 weeks，for Targeted drug therapy alone，at least 2 weeks，must have elapsed at the time of cell infusion;
-
Either having failed or Relapsed after CAR-T therapy at 3 months of assessment;
-
Subjects of child-bearing or child-fathering potential must be willing to practice birth control from the time of enrollment on this study until the follow-up period of the study. Women of childbearing potential must have a negative serum or urine pregnancy test.
-
The viral load of severe coronavirus disease 2019 (COVID-19) is undetectable per quantitative PCR and/or nucleic acid testing for two tests.
Exclusion Criteria:
-
Allergic to any of the components of cell products;
-
Previous or concurrent of other type of maligant tumors;
-
Acute GvHD or generalized chronic GvHD with grade II-IV (Glucksberg standard) after previous autologous hematopoietic stem cell transplantation (auto-HSCT); Or receiving of anti-GVHD therapy;
-
Known history of systemic gene therapy within the prior 3 months;
-
Active systemic fungal, viral, or bacterial infection (except for simple urinary tract infections and bacterial pharyngitis), however, Preventive treatment is permitted;
-
Known history of infection with hepatitis B (HBsAg positive, but HBV-DNA<1000 is not excluded) or hepatitis C virus (including virus carriers), syphilis and other acquired and congenital immunodeficiency diseases, including but not limited to HIV infection;
-
Class III or IV heart failure as defined by the New York Heart Association;
-
Persisting toxicities (>grade 1, except for clinically non-significant toxicities such as alopecia, fatigue, and anorexia) due to prior trerapy;
-
Known history of active seizures or presence of seizure activities or other central nervous system disease;
-
Have evidence of central nervous system lymphoma(CNS lymphoma) on CT or MRI;
-
Breast-feeding woman;
-
Any circumstances that possibly increase the risk of subjects or interfere with study results, which judged by investigator.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Shanghai Tongji Hospital, Tongji University School of Medicine | Shanghai | Shanghai | China | 200065 |
Sponsors and Collaborators
- Aibin Liang，MD，Ph.D.
Investigators
- Study Chair: aibin Liang, Shanghai Tongji Hospital, Tongji University School of Medicine
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 2023-008